BiotechTube

SA4Ag vaccine low dose + SA4Ag vaccine mid dose + SA4Ag vaccine high dose + SA3Ag vaccine + Placebo

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Staphylococcal Infections

Conditions

Staphylococcal Infections

Trial Timeline

Aug 1, 2012 → Mar 1, 2014

NCT ID
NCT01643941

About SA4Ag vaccine low dose + SA4Ag vaccine mid dose + SA4Ag vaccine high dose + SA3Ag vaccine + Placebo

SA4Ag vaccine low dose + SA4Ag vaccine mid dose + SA4Ag vaccine high dose + SA3Ag vaccine + Placebo is a phase 1 stage product being developed by Pfizer for Staphylococcal Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT01643941. Target conditions include Staphylococcal Infections.

What happened to similar drugs?

4 of 5 similar drugs in Staphylococcal Infections were approved

Approved (4) Terminated (2) Active (1)
✅Daptomycin + VancomycinMerckApproved
✅Daptomycin + VancomycinMerckApproved
✅DaptomycinNovartisApproved
✅TigecyclinePfizerApproved
🔄Daptomycin 4 mg/kg + Comparator: vancomycin + Daptomycin 6 mg/kgMerckPhase 3

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01643941Phase 1Completed

Competing Products

20 competing products in Staphylococcal Infections

See all competitors
ProductCompanyStageHype Score
CeftobiproleJohnson & JohnsonPhase 1
29
CeftobiproleJohnson & JohnsonPhase 1
29
Daptomycin + VancomycinMerckApproved
35
Daptomycin 4 mg/kg + Comparator: vancomycin + Daptomycin 6 mg/kgMerckPhase 3
40
V710 + PlaceboMerckPhase 1
29
V710 + Comparator: PlaceboMerckPhase 1
29
V710 (30 µg) with MAA + V710 (30 µg) without MAAMerckPhase 1
29
Daptomycin + VancomycinMerckApproved
43
DaptomycinNovartisApproved
35
SA4Ag vaccinePfizerPhase 1
29
Staphylococcus aureus 4-Antigen (SA4Ag) VaccinePfizerPhase 2
27
linezolid (Zyvox)PfizerPre-clinical
26
Staphylococcus aureus 4-antigen vaccine + PlaceboPfizerPhase 2
35
TigecyclinePfizerApproved
43
SA4Ag vaccine low dose + SA4Ag vaccine mid dose + SA4Ag vaccine high dose + PlaceboPfizerPhase 1
29
NDV-3 vaccine with alum IM + NDV-3 vaccine without alum IM + Placebo with alum IM + NDV-3 vaccine without alum IDUnited TherapeuticsPhase 1
26
NDV-3 investigational vaccineUnited TherapeuticsPhase 1
26
TD-1792 + VancomycinTheravance BiopharmaPhase 2
29
CeftobiproleBasilea PharmaceuticaPhase 1
23
human lactoferrin peptide 1-11AM-PharmaPhase 1/2
14